Emerald Investment Advisers Boosts Stake in Amgen Inc.
Emerald Investment Advisers LLC has increased its stake in Amgen Inc. (NASDAQ: AMGN) by 32.4% during the second quarter, according to a recent filing with the Securities & Exchange Commission.
The fund now owns 15,256 shares of the medical research company's stock after purchasing an additional 3,735 shares during the quarter.
The value of Emerald Investment Advisers LLC's holdings in Amgen was $5,525,000 at the end of the most recent quarter.
Other large investors have also modified their holdings in the company. Roman Butler Fullerton & Co. lifted its stake in shares of Amgen by 1.4% in the second quarter, while High Note Wealth LLC grew its stake in Amgen by 5.8% during the fourth quarter.
The company's stock has been performing well, with analysts raising their outlook and a successful Phase 3 DeLLphi-315 study evaluating a subcutaneous injection of tarlatamab against the current intravenous infusion approach in lung cancer.